MedTrace Logo

Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor

NCT03299452 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-02-15

No results posted yet for this study

Summary

This is a single-center, open-label, single-arm, non-randomized study designed to evaluate PFS, safety, overall survival (OS), objective response rate (OPR), disease control rate (DCR) and biomarkers of cancer therapy based on Alphacait screening system in subjects with advanced malignant tumor.

Conditions

Interventions

DRUG

Non Chemotherapy

Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.

DRUG

Chemotherapy and target therapy

Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.

DRUG

Chinese herb medicine

Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.

Sponsors & Collaborators

  • Alphacait, LLC

    collaborator OTHER

  • Haining Health-Coming Biotech Co., Ltd.

    lead OTHER

Principal Investigators

  • Haizhou Lou, MD · Sir Run Run Shaw Hospital

  • Linghua Zhu, MD · Sir Run Run Shaw Hospital

  • Enguo Chen, MD · Sir Run Run Shaw Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03299452 on ClinicalTrials.gov